BIO-TECHNE Corp APIC, Share-based Payment Arrangement, Increase for Cost Recognition
BIO-TECHNE Corp (TECH) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $40.51 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-24
- BIO-TECHNE Corp apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.93M.
- BIO-TECHNE Corp apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $10.30M, a 9.25% decline year-over-year.
- BIO-TECHNE Corp apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $13.73M, a 4.24% decline year-over-year.
- BIO-TECHNE Corp apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $11.54M, a 13.77% increase year-over-year.
- BIO-TECHNE Corp apic, share-based payment arrangement, increase for cost recognition for fiscal 2026 was $40.51M, a 1.25% increase from fiscal 2025.
- BIO-TECHNE Corp apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $40.01M, a 7.73% increase from fiscal 2024.
- BIO-TECHNE Corp apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $37.14M, a 3.08% decline from fiscal 2023.
- BIO-TECHNE Corp apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $38.31M, a 7.02% decline from fiscal 2022.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.93M derived: 10-K 12 month − 3 quarters · filed 2026-08-24 | $15.24M derived: sum of 2 quarters · filed 2026-08-24 | $28.96M derived: sum of 3 quarters · filed 2026-08-24 | $40.51M 10-K · filed 2026-08-24 |
| 2026-03-31 | $10.30M 10-Q · filed 2026-05-06 | $24.03M derived: sum of 2 quarters · filed 2026-05-06 | $35.58M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2025-12-31 | $13.73M 10-Q · filed 2026-05-06 | $25.27M derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2025-09-30 | $11.54M 10-Q · filed 2026-05-06 | |||
| 2025-06-30 | $40.01M 10-K · filed 2026-08-24 | |||
| 2025-03-31 | $11.36M 10-Q · filed 2026-05-06 | $25.69M derived: sum of 2 quarters · filed 2026-05-06 | $35.84M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $14.34M 10-Q · filed 2026-05-06 | $24.48M derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2024-09-30 | $10.15M 10-Q · filed 2026-05-06 | |||
| 2024-06-30 | $37.14M 10-K · filed 2026-08-24 | |||
| 2024-03-31 | $8.05M 10-Q · filed 2025-05-08 | $20.47M derived: sum of 2 quarters · filed 2025-05-08 | $30.45M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $12.41M 10-Q · filed 2025-05-08 | $22.39M derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2023-09-30 | $9.98M 10-Q · filed 2025-05-08 | |||
| 2023-06-30 | $38.31M 10-K · filed 2025-08-22 | |||
| 2023-03-31 | $9.99M 10-Q · filed 2024-05-06 | $26.41M derived: sum of 2 quarters · filed 2024-05-06 | $40.77M derived: sum of 3 quarters · filed 2024-05-06 | |
| 2022-12-31 | $16.41M 10-Q · filed 2024-05-06 | $30.78M derived: sum of 2 quarters · filed 2024-05-06 | ||
| 2022-09-30 | $14.36M 10-Q · filed 2024-05-06 | |||
| 2022-06-30 | $41.21M 10-K · filed 2024-08-22 | |||
| 2022-03-31 | $8.04M 10-Q · filed 2023-05-08 | $21.74M derived: sum of 2 quarters · filed 2023-05-08 | $33.14M derived: sum of 3 quarters · filed 2023-05-08 | |
| 2021-12-31 | $13.70M 10-Q · filed 2023-05-08 | $25.10M derived: sum of 2 quarters · filed 2023-05-08 | ||
| 2021-09-30 | $11.40M 10-Q · filed 2023-05-08 | |||
| 2021-06-30 | $48.06M 10-K · filed 2023-08-23 | |||
| 2021-03-31 | $10.23M 10-Q · filed 2022-05-09 | $25.70M derived: sum of 2 quarters · filed 2022-05-09 | $38.37M derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $15.47M 10-Q · filed 2022-05-09 | $28.14M derived: sum of 2 quarters · filed 2022-05-09 | ||
| 2020-09-30 | $12.67M 10-Q · filed 2022-05-09 | |||
| 2020-06-30 | $31.93M 10-K · filed 2022-08-24 | |||
| 2020-03-31 | $7.75M 10-Q · filed 2021-05-07 | $17.76M derived: sum of 2 quarters · filed 2021-05-07 | $26.03M derived: sum of 3 quarters · filed 2021-05-07 | |
| 2019-12-31 | $10.02M 10-Q · filed 2021-05-07 | $18.28M derived: sum of 2 quarters · filed 2021-05-07 | ||
| 2019-09-30 | $8.27M 10-Q · filed 2021-05-07 | |||
| 2019-06-30 | $31.77M 10-K · filed 2021-08-25 | |||
| 2019-03-31 | $5.64M 10-Q · filed 2020-05-11 | $12.42M derived: sum of 2 quarters · filed 2020-05-11 | $23.75M derived: sum of 3 quarters · filed 2020-05-11 | |
| 2018-12-31 | $6.78M 10-Q · filed 2020-05-11 | $18.11M derived: sum of 2 quarters · filed 2020-05-11 | ||
| 2018-09-30 | $11.33M 10-Q · filed 2020-05-11 | |||
| 2018-06-30 | $27.96M 10-K · filed 2020-08-26 | |||
| 2018-03-31 | $4.67M 10-Q · filed 2019-05-07 | $9.65M derived: sum of 2 quarters · filed 2019-05-07 | $13.37M derived: sum of 3 quarters · filed 2019-05-07 | |
| 2017-12-31 | $4.99M 10-Q · filed 2019-05-07 | $8.70M derived: sum of 2 quarters · filed 2019-05-07 | ||
| 2017-09-30 | $3.72M 10-Q · filed 2019-05-07 | |||
| 2017-06-30 | $14.42M 10-K/A · filed 2019-11-06 | |||
| 2016-06-30 | $9.29M 10-K · filed 2018-08-27 | |||
| 2015-06-30 | $5.92M 10-K · filed 2017-09-07 | |||
| 2014-06-30 | $3.52M 10-K · filed 2016-08-29 | |||
| 2013-06-30 | $1.86M 10-K · filed 2015-08-31 | |||
| 2012-06-30 | $1.64M 10-K · filed 2014-08-29 | |||
| 2011-06-30 | $1.14M 10-K · filed 2013-08-29 | |||
| 2010-06-30 | $1.14M 10-K · filed 2012-08-29 | |||
| 2009-06-30 | $1.48M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |